Alexion nabs two EU approvals; Sun wraps buyout of GSK opiates biz; Chinese drugmakers poach Indian talent;

@FiercePharma: UPDATED: It's confirmed: 'No signal' of heart failure risk with Merck's Januvia. More | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: No change in CV risk for ACS patients on Sanofi's Lyxumia. Item | Follow @CarlyHFierce

> Alexion Pharmaceuticals ($ALXN) won final European approval for two of its drugs for ultrarare diseases, Kanuma, which treats lysosomal acid lipase deficiency, and Strensiq, a treatment for children with pediatric-onset hypophosphatasia. Report

> Sun Pharmaceutical has wrapped up its buyout of GlaxoSmithKline's ($GSK) opiates business in Australia. Report

> Chinese pharma companies have started recruiting senior scientists from Indian drugmakers to beef up their expertise in formulations, rather than bulk drug ingredients. Report

> Teva Pharmaceutical ($TEVA) said its migraine-relief patch Zecuity is now available in the U.S. Release

> Zeltia said its cancer drug Yondelis won a recommendation for approval in Japan. Report

Medical Device News

@FierceMedDev: Exact Sciences wins CMS panel vote for Cologuard pricing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Quanterix and Banyan Biomarkers forge ahead with brain injury diagnostic tech. Article | Follow @VarunSaxena2

@EmilyWFierce: Social media spin mistress @KimKardashian mops up Duchesnay's marketing mess. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Germany's coramaze receives $5M in Series A to develop transcatheter mitral valve repair device. Article

> CeQur reels in $100M for insulin infusion smart patch device. News

Biotech News

@FierceBiotech: ICYMI: Sanofi buys into Google's biotech future, pairing up in diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Just wondering how Valeant's reps plan to market brodalumab. Suicidal thinking? No worries, mate. Story | Follow @JohnCFierce

@DamianFierce: "Valeant is acquiring __________ for $__________, touting the drug's __________ despite serious concerns about ___________." | Follow @DamianFierce

> Alexion wins a pair of EU approvals to build out its rare disease ranks. Story

> Gene therapy upstart Audentes bags a new program in buyout. More

> CRISPR player Intellia looks IPO-ready after $70M round. Article

Pharma Manufacturing News

> Three pharmaceutical company owners in India busted for distributing pseudoephedrine. Item

> Regis Technologies opens new facility for manufacturing highly potent APIs. Report

> Mega Lifesciences to expand in Indonesia on partnership with Sydna Farma. More

> AMRI, Saneca Pharma team to produce a range of opium-based APIs. Story

> Mayne Pharma to spend $65M on expansion of North Carolina facility. Article

Pharma Asia News

> Two dengue treatments slated for PhII in Singapore next year. Report

> Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications. Item

> Another recall by Indian drugmakers as U.S. FDA notes troubles. More

> Executive shakeup with Guilder out at Taiwan's TWi. Story

> Shanghai Pharmaceutical raises funds for online-to-offline sales push with eye on ethical products. Article

Drug Delivery News

> Surefire picks up FDA clearance for Precision cancer drug delivery tool. More

> MicroRNA specialist aims for $81M IPO amid market downturn. Report

> Teva makes only approved migraine patch available in the U.S. Story

> Intraoperative radiation therapy proving divisive among oncologists. Item

> Titan Pharma submits opioid addiction-fighting subdermal implant for FDA approval. Article

And Finally... New guidelines from the American Society of Clinical Oncology aim to help doctors make sense of newly available genetic testing. Report

Suggested Articles

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Ind

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.